source
- Eli Lilly to acquire Calytrix Bio for up to $1.5 billion to add blood-cancer assetsEli Lilly announced it will acquire privately held Calytrix Bio in a deal valued at up to $1.5 billion in cash. The acquisition is Lilly’s 14th buyout this year and adds a blood-cancer program to…
- Seawolf Therapeutics raises $100M and secures up to $1.2B partnership with SanofiSeawolf Therapeutics, a San Diego-based DNA-therapy startup, announced a $100 million financing round as it emerges from stealth. The round was led by Versant Ventures with participation from MPM…